SOURCE: Ora, Inc.

Ora, Inc.

May 23, 2011 10:23 ET

Ora Expert Presents Latest Information on Dry Eye Therapy Pipeline at Ocular Diseases & Drug Discovery Conference

ANDOVER, MA--(Marketwire - May 23, 2011) - George Ousler, Vice President, Dry Eye, Ora, Inc., will present the Dry Eye Pipeline session at GTCbio's 3rd Annual Ocular Diseases & Drug Discovery Conference on Friday, May 27 at the Seaport Hotel in Boston, MA. Mr. Ousler is joining other leading scientists, researchers, and experts to discuss and collaborate on the latest research and drugs available in combating and curing a wide array of eye diseases, including Dry Eye, glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).

Mr. Ousler spent nearly 15 years of his career pioneering pharmaceutical development in the area of Dry Eye. He authored over 100 publications, and has been invited to present his research at numerous national and international symposia. He serves on several noted Dry Eye research committees, including the Dry Eye Workshop (DEWS), devoted to identifying the appropriate diagnostic tools and methods to evaluate this disease. As the Vice President of the Dry Eye Department at Ora, he is responsible for developing clinical models and regulatory pathways for the evaluation of dry eye therapies, and has conducted the studies of virtually all of the agents currently under investigation.

"Because of the continued investments we've made in our Dry Eye research models over the past 15 years, Ora's Dry Eye department now offers a combination of technology and expertise that no other development firm in the world can match," explained Ousler. "We are fortunate enough to be currently working with several of the world's leading dry eye pioneers to develop the next generation of dry eye treatments."

During his GTCbio presentation on the current Dry Eye development pipeline, Mr. Ousler will offer key insights into clinical trial design, the newest technologies available for studying dry eye, and the best ways to identify patient sub-groups and promising drug candidates. Ousler's presentation will be at 10:40 am on Friday, May 27.

About Ora
Ora, Inc. (www.oraclinical.com) is the world's leading independent ophthalmic product development firm, with 32 product approvals during its 30-year history. Ora helps clients garner FDA approvals by providing strategic clinical-regulatory guidance and complete turnkey clinical-regulatory services. Ora's technology-based, concept-to-market services and solutions accelerate development timelines and improve the scientific quality of clinical research along every step of the development pathway.

Contact Information